BioPharmSignal logoBioPharmSignal

Biotech News

Enanta Pharmaceuticals to Participate in Upcoming Investor Conferences

Enanta Pharmaceuticals (ENTA)Enanta PharmaceuticalsCompany update

WATERTOWN, Mass. --(BUSINESS WIRE)--Nov. 4, 2026-- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and immunological diseases, today announced that members of management will participate in the

Related news

ENTAEnanta Pharmaceuticals2026-10-28 11:00 EST

Enanta Pharmaceuticals Announces Planned Retirement of Longstanding Chief Executive Officer Jay R. Luly, Ph.D. After 23 Years of Company Leadership

ENTAEnanta Pharmaceuticals2026-10-26 11:00 EST

Enanta Pharmaceuticals Announces First Patient Dosed in the RESOLVE Phase 2b/3 Study of Zelicapavir, a Potential First-in-Disease Treatment for Respiratory Syncytial Virus (RSV)

CABACabaletta Bio2026-11-03 13:00 EST

Cabaletta Bio to Participate in Upcoming Investor Conferences

AVTXAvalo Therapeutics2026-11-02 21:00 EST

Avalo Therapeutics to Participate in Upcoming Investor Conferences

XGNExagen2026-10-29 13:00 EST

Exagen Inc. to Participate in Upcoming Investor Conferences

ANTXAN2 Therapeutics2026-10-20 20:13 EST

AN2 Therapeutics to Participate at Upcoming Investor Conferences

IMNNImunon2026-10-08 13:00 EST

IMUNON to Participate in Upcoming Investor Conferences

XFORX4 Pharmaceuticals2026-11-03 21:30 EST

X4 Pharmaceuticals to Participate in Guggenheim, Stifel, and Jefferies Conferences in November 2026

BCRXBioCryst Pharmaceuticals2026-11-04 21:01 EST

BioCryst to Present at Upcoming Investor Conferences

EXELExelixis2026-11-03 21:05 EST

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in November

View all latest news

Enanta Pharmaceuticals

Small-Molecule Research Platform Enanta Pharmaceuticals discovers and develops oral small molecules for virology and immunology. Its portfolio applies structure-based drug design to targets that may support convenient, once-daily treatment. EDP-978 KIT Inhibitor EDP-978 is an oral KIT inhibitor in Phase 1 development for chronic...

Recent company news

ENTAEnanta Pharmaceuticals2026-11-04 12:00 EST

Enanta Pharmaceuticals to Participate in Upcoming Investor Conferences

ENTAEnanta Pharmaceuticals2026-10-28 11:00 EST

Enanta Pharmaceuticals Announces Planned Retirement of Longstanding Chief Executive Officer Jay R. Luly, Ph.D. After 23 Years of Company Leadership

ENTAEnanta Pharmaceuticals2026-10-26 11:00 EST

Enanta Pharmaceuticals Announces First Patient Dosed in the RESOLVE Phase 2b/3 Study of Zelicapavir, a Potential First-in-Disease Treatment for Respiratory Syncytial Virus (RSV)

ENTAEnanta Pharmaceuticals2026-10-13 11:00 EST

Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at IDWeek™ 2026

ENTAEnanta Pharmaceuticals2026-09-01 11:00 EST

Enanta Pharmaceuticals to Participate in September Investor Conferences

Stock data

Close
10.08 USD
Market cap
349.81M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States